Pallas Capital Advisors LLC Purchases New Stake in Bruker Corporation $BRKR

Pallas Capital Advisors LLC acquired a new position in shares of Bruker Corporation (NASDAQ:BRKR) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 9,483,978 shares of the medical research company’s stock, valued at approximately $570,746,000. Bruker accounts for approximately 17.6% of Pallas Capital Advisors LLC’s portfolio, making the stock its largest position. Pallas Capital Advisors LLC owned approximately 6.23% of Bruker as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Los Angeles Capital Management LLC acquired a new position in shares of Bruker during the 4th quarter worth $26,000. Allworth Financial LP lifted its stake in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the period. Essential Partners LLC purchased a new stake in Bruker during the first quarter worth about $36,000. Global Retirement Partners LLC acquired a new position in Bruker during the second quarter worth about $38,000. Finally, Parallel Advisors LLC grew its position in Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after buying an additional 479 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Performance

Shares of BRKR opened at $57.67 on Tuesday. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $65.30. The stock has a market cap of $8.79 billion, a P/E ratio of -82.39, a PEG ratio of 1.76 and a beta of 1.28. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The company has a 50-day moving average of $58.39 and a two-hundred day moving average of $47.11.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm had revenue of $838.50 million during the quarter, compared to analysts’ expectations of $853.57 million. During the same quarter last year, the business posted $0.32 EPS. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s payout ratio is -28.57%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BRKR. Zacks Research upgraded shares of Bruker from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 4th. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Leerink Partners lifted their price objective on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Finally, Citigroup decreased their target price on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Bruker has a consensus rating of “Moderate Buy” and a consensus target price of $56.64.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.